Skip to main content
. 2024 Jun 1;104:105170. doi: 10.1016/j.ebiom.2024.105170

Fig. 1.

Fig. 1

Therapeutic effects of anti-EBOV-GP antibodies on weight change, survival and lymphopenia in VSV-EBOV-infected mice. (a) Virus neutralization by antibodies: SAB-139 (polyAb), REGN3478 (ADCC-mAb), and REGN3481 (NEUT-mAb) or the combination of ADCC-mAb and NEUT-mAb using VERO E6 cells infected with replicating VSV-EBOV (MOI 0.1). Data are representative of three independent experiments. (b–d) P3 C57BL/6 mice were subcutaneously (s.c.) infected with 1000 TCID50 of VSV-EBOV and intraperitoneally (i.p.) treated with human IgG isotype controls (IgG control; 100 mg/kg, (b) n = 9, (c) n = 17, or (d) n = 6, respectively), polyAb (100 mg/kg, (b) n = 3, (c) n = 12, or (d) n = 6), ADCC-mAb (100 mg/kg, (b) n = 10, (c) n = 13, or (d) n = 6), NEUT-mAb (100 mg/kg, (b) n = 8, (c) n = 12, or (d) n = 8) or the combination of ADCC-mAb and NEUT-mAb (50 mg/kg, each, (b) n = 11, (c) n = 10, or (d) n = 6) at 3 dpi. Mice were monitored for weight changes (b) and survival (c). Data are shown as mean ± standard deviation (SD). Statistical significance was determined using a two-way ANOVA (mixed-effects model with the Geisser-Greenhouse correction) (b) and the log-rank test (c), respectively. ∗∗∗P < 0.001 compared to infected mice treated with IgG control. (d) Hematological assessment at 9 dpi. Table shows incidence of lymphopenia by 9 dpi.